Loading data for NEO — first visit, this takes a few seconds.

Alerte

NeoGenomics Inc. (NEO)

NasdaqCM: NEO · Prix en temps réel · USD

16.41

-0.57 (-3.36%)

À la clôture : Aug 26, 2026, 3:59 PM

Le cours, les chiffres clés et les dernières actualités, au même endroit.

-3.36% (1D)

Cours acheteur	11.97
Capitalisation boursière	2.11B
Chiffre d’affaires (ttm)	766.29M
Résultat net (ttm)	-51.88M
	1.73
	-0.38
	n/a
	47.75
P/B (ttm)	2.67
P/S (ttm)	2.79
Date des résultats	Apr 29, 2025

Cours vendeur	20.49
Volume	1,093,873
Volume moy. (20D)	2,796,361
Ouverture	16.75
Clôture précédente	16.98
Fourchette du jour	16.28 - 16.80
Intervalle de 52 semaines	6.41 - 17.08
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[En savoir plus]

Industrie Diagnostics & Research

Secteur Healthcare

Date d’introduction Mar 16, 2004

Employés 2,500

Bourse NasdaqCM

Symbole boursier NEO

Site web https://www.neogenomics.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de NeoGenomics s’élevait à 727.33M, soit une hausse de 10.11% par rapport aux 660.57M de l’année précédente. Le bénéfice s’élevait à -108.03M, soit une hausse de 37.22%.

États financiers

Surprise sur les résultats

NeoGenomics a publié ses résultats trimestriels le Jul 28, 2026 :

Chiffre d’affaires de $201.66M est inférieur aux estimations de $0, avec 11.21% croissance en glissement annuel.
EPS de 0.05 dépasse les estimations de 0.02, avec 66.67% croissance en glissement annuel.

Prochaine publication des résultats

NeoGenomics Inc. devrait publier ses résultats le Apr 29, 2025, avant l’ouverture du marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

3 jours il y a · Zacks

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

6 jours il y a · StockStory

3 Unprofitable Stocks Walking a Fine Line

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital ...

2 semaines il y a · StockStory

3 Stocks Under $50 with Open Questions

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

2 semaines il y a · Simply Wall St.

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

3 semaines il y a · Zacks

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Page 1 de 2

NeoGenomics Inc. (NEO)